Table 2.
Patient characteristics for each of four conditioning regimen groups, n (%)
| MA-noTBI (n = 38) | MA+TBI (n = 51) | RIC-noTBI (n = 118) | RIC+TBI (n = 40) | P | |
| Age at BMT | < 0.0001 | ||||
| Median-years (range) | 47 (26-58) | 36 (19-51) | 54 (23-73) | 61 (23-71) | |
| < 40 | 6 (16) | 29 (57) | 22 (19) | 3 (8) | |
| ≥ 40 | 32 (84) | 22 (43) | 96 (81) | 37 (93) | |
| Gender | NS | ||||
| Female | 21 (55) | 19 (37) | 45 (38) | 22 (55) | |
| Male | 17 (45) | 32 (63) | 73 (62) | 18 (45) | |
| Diagnosis | < 0.0001 | ||||
| ALL | 0 | 20 (39) | 7 (6) | 6 (15) | |
| AML | 11 (29) | 28 (55) | 58 (49) | 14 (35) | |
| CML | 7 (18) | 1 (2) | 3 (3) | 1 (3) | |
| MDS/MPD | 11 (29) | 1 (2) | 23 (19) | 10 (25) | |
| NHL/CLL/PLL | 8 (21) | 1 (2) | 25 (21) | 8 (20) | |
| Other | 1 (3) | 0 | 2 (2) | 1 (3) | |
| Karnofsky Performance Status | 0.03 | ||||
| ≤ 70 | 8 (21) | 8 (16) | 35 (30) | 13 (33) | |
| 80 | 13 (34) | 15 (29) | 51 (43) | 14 (35) | |
| ≥ 90 | 17 (45) | 28 (55) | 32 (27) | 13 (33) | |
| BMT Regimen | < 0.0001 | ||||
| BuCy | 36 (95) | 0 | 0 | 0 | |
| CyTBI | 0 | 47 (92) | 0 | 0 | |
| FluCy | 0 | 0 | 12 (10) | 0 | |
| FluMel | 0 | 0 | 102 (86) | 0 | |
| FluMelTBI | 0 | 0 | 0 | 40 (100) | |
| Other | 2 (5) | 4 (8) | 4 (3) | 0 | |
| Sex Match | NS | ||||
| Matched | 24 (63) | 30 (59) | 70 (59) | 27 (68) | |
| Mismatched | 14 (37) | 21 (41) | 48 (41) | 13 (33) | |
| Donor | < 0.0001 | ||||
| HLA Matched Related | 33 (87) | 31 (61) | 54 (46) | 17 (43) | |
| HLA Matched Unrelated | 5 (13) | 20 (39) | 64 (54) | 23 (58) | |
| GvHD Prophylaxis | < 0.0001 | ||||
| TacMtx | 18 (47) | 35 (69) | 33 (28) | 0 | |
| TacMMF | 4 (11) | 2 (4) | 18 (15) | 0 | |
| TacmMtxMMF | 15 (39) | 7 (14) | 64 (54) | 40 (100) | |
| Single Agent | 1 (3) | 7 (14) | 3 (3) | 0 | |
| CMV Status | NS | ||||
| R+D+ | 6 (16) | 8 (16) | 28 (24) | 9 (23) | |
| R+D- | 14 (37) | 12 (24) | 35 (30) | 12 (30) | |
| R-D+ | 0 | 8 (16) | 18 (15) | 4 (10) | |
| R-D- | 18 (47) | 23 (45) | 37 (31) | 15 (38) | |
| BMI kg/m2 | NS | ||||
| Normal (< 30) | 15 (39) | 25 (49) | 34 (29) | 13 (33) | |
| Overweight (25-< 30) | 12 (32) | 14 (27) | 40 (34) | 15 (38) | |
| Obese (≥ 30-< 35) | 7 (18) | 7 (14) | 28 (24) | 7 (18) | |
| Morbid (≥ 35) | 4 (11) | 5 (10) | 16 (14) | 5 (13) |
MA: Myeloablative; TBI: Total body irradiation; RIC: Reduced intensity conditioning; ALL: Acute lymphoid leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder; NHL: Non-Hodgkin lymphoma; CLL: Chronic lymphocytic leukemia; PLL: Prolymphocytic leukemia; Bu: Busulfan; Cy: Cyclophosphamide; Flu: Fludarabine; Mel: Melphalan; Tac: Tacrolimus; Mtx: Methotrexate; mMt: Micro dose methotrexate; MMF: Mycophenylate mofetil ; R: Recipient; D: Donor; BMI: Body mass index; NS: Not significant (P > 0.05).